



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: Angela M. Caliendo, M.D., Ph.D., FIDSA, FAAM

Committee: Microbiology Devices Panel of the Medical Devices Advisory Committee

Meeting Date: September 8, 2023

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: For the second session on September 8, 2023, the Panel will discuss and provide advice regarding topics related to in vitro diagnostic (IVD) medical devices used in pandemic preparedness and response to satisfy, in part, Section 3302 of the Food and Drug Omnibus Reform Act of 2022, which was signed into law as part of the Consolidated Appropriations Act, 2023, Pub. L. No. 117-328 (“FDORA”), I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stockholdings/Investment	Affected firms (two)	Combined value between \$500,001 and \$725,000
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/S/
Signature

July 20, 2023
Date